Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial

被引：0
|
作者：
Eggermont, A. M. M. [1 ]
Suciu, S. [1 ]
Santinami, M. [1 ]
Testori, A. [1 ]
Kruit, W. [1 ]
Marsden, J. [1 ]
Punt, C. J. A. [1 ]
Sales, F. [1 ]
Gore, M. [1 ]
Mckie, R. [1 ]
Kusic, V. [1 ]
Dummer, R. [1 ]
Musat, E. [1 ]
Spatz, A. [1 ]
Keilholz, U. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, NL-3000 DR Rotterdam, Netherlands
来源：
PIGMENT CELL & MELANOMA RESEARCH | 2008年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [41] Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
    Weber, J. S.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J. J.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Butler, M. O.
    Maio, M.
    Middleton, M. R.
    Tang, T.
    Saci, A.
    De Pril, V.
    Lobo, M.
    Larkin, J. M. G.
    Ascierto, P. A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 533 - +
  • [42] Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma:: An Eastern Cooperative Oncology Group study
    Falkson, CI
    Ibrahim, J
    Kirkwood, JM
    Coates, AS
    Atkins, MB
    Blum, RH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1743 - 1751
  • [43] Final results of the EORTC 18871/DKG 80-1 randomised phase III trial:: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
    Kleeberg, UR
    Suciu, S
    Bröcker, EB
    Ruiter, DJ
    Chartier, C
    Liénard, D
    Marsden, J
    Schadendorf, D
    Eggermont, AMM
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) : 390 - 402
  • [44] Adjuvant Nivolumab (NIVO) Versus Ipilimumab (IPI) in Resected Stage III/IV Melanoma: 3-Year Efficacy and Biomarker Results From the Phase 3 Checkmate 238 Trial
    Weber, J.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Butler, M.
    Maio, M.
    Vetto, J.
    Tang, H.
    Saci, A.
    de Pril, V.
    Lobo, M.
    Larkin, J.
    Ascierto, P. A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S144 - S144
  • [45] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
    Chiarion-Sileni, V.
    Guida, M.
    Romanini, A.
    Ridolfi, R.
    Mandala, M.
    Del Bianco, P.
    Silvestri, B.
    Medici, M.
    Michiara, M.
    Dalla Palma, M.
    Puccetti, O.
    Pigozzo, J.
    Laveder, F.
    De Salvo, G. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma
    Muggiano, A
    Mulas, C
    Fiori, B
    Liciardi, G
    Pintus, M
    Tanca, L
    Tedde, A
    Turno, R
    Desogus, A
    [J]. MELANOMA RESEARCH, 2004, 14 (02) : S1 - S7
  • [47] A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
    Mao, Lili
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Li, Siming
    Tang, Bixia
    Guo, Jun
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1498 - 1503
  • [48] CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)
    Riess, H.
    Neuhaus, P.
    Post, S.
    Gellert, K.
    Ridwelski, K.
    Schramm, H.
    Zuelke, C.
    Fahlke, J.
    Langrehr, J.
    Oettle, H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 45 - 46
  • [49] CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)
    Neuhaus, P.
    Riess, H.
    Post, S.
    Gellert, K.
    Ridwelski, K.
    Schramm, H.
    Zuelke, C.
    Fahlke, J.
    Langrehr, J.
    Oettle, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)
    Weber, Jeffrey S.
    Mandala, Mario
    Del Vecchio, Michele
    Gogas, Helen
    Arance, Ana M.
    Cowey, C. Lance
    Dalle, Stephane
    Schenker, Michael
    Chiarion-Sileni, Vanna
    Marquez-Rodas, Ivan
    Grob, Jean-Jacques
    Butler, Marcus
    Middleton, Mark R.
    Maio, Michele
    Atkinson, Victoria
    Dummer, Reinhard
    de Pril, Veerle
    Qureshi, Anila
    Larkin, James
    Ascierto, Paolo A.
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 41 - 42
12345